OncoMatch/Clinical Trials/NCT06158399
AZA Combined With RCHOP in P53-mutated DLBCL.
Is NCT06158399 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Azacitidine in combination with R-CHOP for dlbcl - diffuse large b cell lymphoma.
Treatment: Azacitidine in combination with R-CHOP — To evaluate the efficacy and adverse effects of Azacitidine in combination with R-CHOP (ARCHOP) for the treatment of TP53-mutated previously untreated Diffuse large B-cell lymphoma
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Diffuse Large B-Cell Lymphoma
Non-Hodgkin Lymphoma
Biomarker criteria
Required: TP53 mutation
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Lab requirements
Kidney function
serum cr ≤ 2.0 × uln (unless due to lymphoma)
Liver function
serum bilirubin ≤ 2.0 × uln, serum alt and ast ≤ 2.5 × uln
Cardiac function
lvef >45%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06158399 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require TP53?
Yes, TP53 mutation is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 70 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify